Metagenomi, Inc. Common Stock (MGX) NASDAQ

1.55

-0.04(-2.52%)

Updated at May 09 11:00AM

Currency In USD

Metagenomi, Inc. Common Stock

Address

5959 Horton Street

Emeryville, 94608

United States of America

Phone

510-871-4880

Sector

Healthcare

Industry

Biotechnology

Employees

202

First IPO Date

April 06, 2006

Key Executives

NameTitlePayYear Born
Dr. Brian Charles Thomas Ph.D.Co-Founder, Chief Executive Officer & Chairman of the Board913,2991969
Ms. Pamela M. Wapnick M.B.A.Chief Financial Officer581,8131966
Dr. Sarah B. Noonberg M.D., Ph.D.Chief Medical Officer591,4941968
Dr. Jian Irish M.B.A., Ph.D.President, Chief Operating Officer & Director734,6261964
Dr. Joseph Knowles M.D.Co-Founder & Member of Scientific Advisory Board0N/A
Mr. Matthew L. Wein J.D.Senior Vice President, Head of Legal, Compliance Officer & Corporate Secretary01971
Dr. Alan Brooks Ph.D.Head of Preclinical01966
Dr. Christopher BrownHead of Discovery01989

Description

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.